Table 2.
Anthropometric and clinical characteristic at baseline (T0) and after hazelnut treatment (HNT) (T1).
| Baseline (T0) | HNT (T1) | Δ% | p | |||
|---|---|---|---|---|---|---|
| Median | Min–Max | Median | Min–Max | |||
| SBP (mmHg) | 116.50 | 96.00-169.00 | 120.00 | 100.00-150.00 | 3.00 | 0.81a |
| DBP (mmHg) | 73.00 | 57.00-93.00 | 75.00 | 60.00-86.00 | 2.74 | 0.28a |
| Weight (kg) | 71.40 | 53.50-93.00 | 71.05 | 53.50-93.00 | -0.49 | 0.46a |
| BMI (kg/m2) | 25.95 | 20.64-35.60 | 25.76 | 20.64-35.44 | -0.71 | 0.55a |
| Neck circumference (cm) | 39.50 | 33.00-44.00 | 40.00 | 34.00-43.00 | 1.27 | 0.71b |
| Waist circumference (cm) | 86.25 | 66.50-101.00 | 85.00 | 66.00-103.00 | -1.45 | 0.90a |
| Abdominal circumference (cm) | 94.00 | 73.00-110.00 | 93.50 | 81.00-110.50 | -0.53 | 0.04a |
| Hip circumference (cm) | 98.25 | 92.00-117.00 | 99.00 | 91.00-116.00 | 0.76 | 0.44b |
| Waist/hip ratio | 0.87 | 0.71-1.03 | 0.87 | 0.69-1.00 | 0.00 | 0.34a |
| TBFat (kg) | 34.75 | 14.60-53.10 | 34.95 | 13.50-52.60 | 0.58 | 0.89b |
| TBFat (%) | 29.65 | 16.3-54 | 29.05 | 18.00-53.30 | -2.02 | 0.73a |
| ABFat (%) | 28.75 | 16.10-48.30 | 28.80 | 15.40-48.00 | 0.17 | 0.15a |
| GBFat (%) | 21.08 | 12.02-38.02 | 21.34 | 12.49-38.13 | 1.21 | 0.89a |
| TBLean (kg) | 47.63 | 32.87-70.81 | 48.09 | 32.40-68.42 | 0.97 | 0.34a |
| BMC (g) | 2703.00 | 1667.00-3742.00 | 2622.00 | 1692.00-3627.00 | -3.00 | 0.29a |
| ASMMI | 8.37 | 5.98-10.28 | 8.05 | 6.06-10.57 | -3.83 | 0.11a |
| t-score | -0.1000 | -1.90-1.90 | -0.1000 | -1.90-1.90 | 0.00 | 0.87a |
| Neutrophils (K/μL) | 2970.00 | 2220-6860 | 3245 | 2170-8481 | 11.71 | 0.40a |
| Lymphocytes (K/μL) | 1695.00 | 1160.00-2680.00 | 1660.00 | 754.00-2700.00 | -7.11 | 0.18b |
| Platelets (K/μL) | 194500.00 | 166000.00-293000.00 | 214000.00 | 148000.00-324000.00 | 6.01 | 0.14a |
| TC (mg/dL) | 181.00 | 149.00-214.00 | 167.00 | 102.00-200.00 | -10.48 | 0.01a |
| HDL-C (mg/dL) | 51.50 | 35.00-79.00 | 47.50 | 37.00-80.00 | -6.93 | 0.22a |
| LDL-C (mg/dL) | 114.00 | 75.00-146.00 | 103.00 | 47.00-125.00 | -12.12 | 0.01a |
| Tg (mg/dL) | 100.50 | 42.00-170.00 | 82.50 | 44.00-151.00 | -11.99 | 0.20a |
| NLR | 2.08 | 0.83-4.48 | 2.14 | 0.95-6.68 | 28.87 | 0.18b |
| PLR | 127.08 | 61.94-198.28 | 135.69 | 64.91-309.02 | 18.10 | 0.08a |
| Tg/HDL-C | 2.02 | 0.68-3.55 | 1.87 | 0.61-3.02 | -5.61 | 0.55b |
| TC/HDL-C | 3.71 | 2.28-5.03 | 3.27 | 2.23-4.6 | -5.83 | 0.03a |
| kcal/diet | 1965.00 | 1230.00-2780.00 | 2226.99 | 1491.99-3041.99 | 11.38 | 0.03a |
Anthropometric and clinical characteristic at baseline (T0) and after HNT (T1). Results are expressed as the median, minimum, and maximum for each parameter. A paired t-test (a) or a nonparametric Wilcoxon test (b) was performed to evaluate differences before and after hazelnut intervention. All tests were considered significant at p ≤ 0.05. SBP: systolic blood pressure; DBP: diastolic blood pressure; TBFat: total body fat; ABFat: android body fat; GBFat: gynoid body fat; TBLean: total body lean; BMC: bone mineral content; ASMMI: appendicular skeletal muscle mass index; TC: total cholesterol; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; Tg: triglycerides; NLR: neutrophil-lymphocyte ratio; PLR: platelet-lymphocyte ratio.